MedTrace Logo

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

NCT05007236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2022-04-21

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age \> 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity, cancer) for developing severe Covid-19 illness.

Conditions

Interventions

DRUG

RP7214 + Standard of care (SOC)

RP7214 tablets will be administered orally twice a day for 14 days

DRUG

Placebo + Standard of care (SOC)

Placebo will be administered orally twice a for 14 days

Sponsors & Collaborators

  • Incozen Therapeutics Pvt Ltd

    collaborator UNKNOWN

  • Rhizen Pharmaceuticals SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2022-03-25
Completion
2022-03-25

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007236 on ClinicalTrials.gov